# Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer

> **NCT00083031** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 57 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** bevacizumab
- **DRUG:** cyclophosphamide
- **DRUG:** methotrexate

## Key facts

- **NCT ID:** NCT00083031
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** 2006-08
- **Final completion:** 2009-08
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2019-05-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00083031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00083031, "Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00083031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*